Sutro Biopharma, Inc.

NasdaqGM STRO

Sutro Biopharma, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2024: 71,433,980

Sutro Biopharma, Inc. Shares (Diluted, Weighted) is 71,433,980 for the Trailing 12 Months (TTM) ending September 30, 2024, a 20.85% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Sutro Biopharma, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2023 was 59,112,007, a 23.17% change year over year.
Sutro Biopharma, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2022 was 47,991,268, a 9.65% change year over year.
Sutro Biopharma, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2021 was 43,768,393, a 50.86% change year over year.
Sutro Biopharma, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2020 was 29,012,863, a 26.69% change year over year.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

NasdaqGM: STRO

Sutro Biopharma, Inc.

CEO	Mr. William J. Newell J.D.
IPO Date	Sept. 27, 2018
Location	United States
Headquarters	111 Oyster Point Boulevard
Employees	302
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Key trends

Past 5 years